Amgen

Advancements in Italian oncology and radiotherapy

3 clusters · 32 sources · last updated 2 days ago

Latest: Italy advances personalized oncology and leukemia immunotherapy

Italian medical institutions continue to advance oncology through specialized training, genomic profiling, and personalized care models. To support genomic cancer profiling for approximately 15,000 eligible patients ann

Sandoz biosimilar business expansion

2 clusters · 3 sources · last updated 11 days ago

Latest: Sandoz to invest USD 300 million in Slovenian biosimilar facility

Sandoz is expanding its biosimilar business through strategic partnerships and infrastructure investment. In August 2026, the company entered a $322 million collaboration with Shanghai Henlius Biotech to develop and comm

Novartis CAR T cell therapy trial suspensions

2 clusters · 34 sources · last updated 13 days ago

Latest: Novartis shares plunge following dual clinical trial failures

Novartis has halted eight clinical trials involving an experimental CAR T cell therapy following three deaths. The fatalities were linked to immune effector cell-associated hemophagocytic syndrome (IEC-HS), a condition w

Tavneos drug recall in Europe

2 clusters · 6 sources · last updated 18 days ago

Latest: Tavneos drug recalled in Hungary following EU safety concerns

The prescription drug Tavneos, used to treat rare autoimmune inflammatory vascular diseases, is being withdrawn from European markets following safety concerns. In August 2026, the French National Agency for the Safety

Schwab U.S. Dividend Equity ETF performance and strategy

3 clusters · 9 sources · last updated 25 days ago

Latest: Schwab U.S. Dividend Equity ETF sees significant inflows amid defensive shift

Investors evaluating dividend-focused exchange-traded funds (ETFs) continue to weigh the Schwab U.S. Dividend Equity ETF (SCHD) against high-yield and growth-oriented alternatives. SCHD maintains a low-cost, lower-volati